What do We Know so Far about Ges Carbapenemases, and What Threat do They Pose?

1. Aguirre-Quiñonero A., Cano M.E., Gamal D., Calvo J., Martínez-Martínez L.: Evaluation of the carbapenem inactivation method (CIM) for detecting carbapenemase activity in enterobacteria. Diagn Microbiol Infect Dis. 88(3), 214–218 (2017) Aguirre-Quiñonero A. Cano M.E. Gamal D. Calvo J. Martínez-Martínez L. : Evaluation of the carbapenem inactivation method (CIM) for detecting carbapenemase activity in enterobacteria . Diagn Microbiol Infect Dis . 88 ( 3 ), 214 – 218 ( 2017 ) Search in Google Scholar

2. Ambler R.P., Coulson A.F., Frère J.M., Ghuysen J.M., Joris B., Forsman M., Levesque R.C., Tiraby G., Waley S.G.: A standard numbering scheme for the class A beta-lactamases. Biochem J. 276, 269–270 (1991) Ambler R.P. Coulson A.F. Frère J.M. Ghuysen J.M. Joris B. Forsman M. Levesque R.C. Tiraby G. Waley S.G. : A standard numbering scheme for the class A beta-lactamases . Biochem J . 276 , 269 – 270 ( 1991 ) Search in Google Scholar

3. Barlow M., Tenover F.C.: Phylogenetic predictions of carbapenemase activity from the Guiana extended-spectrum (GES) family of β-lactamases. JAC Antimicrob Resist, 6, dladl50 (2024). Barlow M. Tenover F.C. : Phylogenetic predictions of carbap-enemase activity from the Guiana extended-spectrum (GES) family of β-lactamases . JAC Antimicrob Resist , 6 , dladl50 ( 2024 ). Search in Google Scholar

4. Bebrone C., Bogaerts P., Delbrück H., Bennink S., Kupper M.B., Rezende de Castro R., Glupczynski Y., Hoffmann K.M.: GES-18, a new carbapenem-hydrolyzing GES-Type β-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues. Antimicrob Agents Chemother. 57(1), 396–401 (2013) Bebrone C. Bogaerts P. Delbrück H. Bennink S. Kupper M.B. Rezende de Castro R. Glupczynski Y. Hoffmann K.M. : GES-18, a new carbapenem-hydrolyzing GES-Type β-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues . Antimicrob Agents Chemother . 57 ( 1 ), 396 – 401 ( 2013 ) Search in Google Scholar

5. Bonnin R.A., Jousset A.B., Urvoy N., Gauthier L., Tlili L., Creton E., Cotellon G., Arthur F., Dortet L., Naas T.: Detection of GES-5 Carbapenemase in Klebsiella pneumoniae, a Newcomer in France. Antimicrob. Agents Chemother. 61, 02263–16 (2017) Bonnin R.A. Jousset A.B. Urvoy N. Gauthier L. Tlili L. Creton E. Cotellon G. Arthur F. Dortet L. Naas T. : Detection of GES-5 Carbapenemase in Klebsiella pneumoniae, a Newcomer in France . Antimicrob. Agents Chemother . 61 , 02263 – 16 ( 2017 ) Search in Google Scholar

6. Bonnin R.A., Rotimi V.O., Al Hubail M., Gasiorowski E., Al Sweih N., Nordmann P., Poirel L.: Wide dissemination of GES-type carbapenemases in Acinetobacter baumannii isolates in Kuwait. Antimicrob. Agents Chemother. 57, 183–188 (2013) Bonnin R.A. Rotimi V.O. Al Hubail M. Gasiorowski E. Al Sweih N. Nordmann P. Poirel L. : Wide dissemination of GES-type carbapenemases in Acinetobacter baumannii isolates in Kuwait . Antimicrob. Agents Chemother . 57 , 183 – 188 ( 2013 ) Search in Google Scholar

7. Bonnin R.A., Nordmann P., Potron A., Lecuyer H., Zahar J.R., Porel L.: Carbapenem-hydrolyzing GES-type extended-spectrum β-lactamase in Acinetobacter baumanii. Antimicrob Agents Chemother, 55, 349–354 (2011) Bonnin R.A. Nordmann P. Potron A. Lecuyer H. Zahar J.R. Porel L. : Carbapenem-hydrolyzing GES-type extended-spectrum β-lactamase in Acinetobacter baumanii . Antimicrob Agents Chemother , 55 , 349 – 354 ( 2011 ) Search in Google Scholar

8. Bonnin R.A., Jousset A.B., Emeraud C., Oueslati S., Dortet L., Naas T.: Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales. Front Med (Lausanne) 7 (2021) Bonnin R.A. Jousset A.B. Emeraud C. Oueslati S. Dortet L. Naas T. : Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales . Front Med (Lausanne) 7 ( 2021 ) Search in Google Scholar

9. Bonnin R.A., Jousset A.B., Emeraud C., Oueslati S., Dortet L., Naas T.: Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales., Front. Med. 7 (2021) Bonnin R.A. Jousset A.B. Emeraud C. Oueslati S. Dortet L. Naas T. : Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales ., Front. Med . 7 ( 2021 ) Search in Google Scholar

10. Bonomo R.A., Burd E.M., Conly J., Limbago B.M., Poirel L., Segre J.A., Westblade L.F.: Carbapenemase-Producing Organisms: A Global Scourge. Clin. Infect. Dis. 66, 1290–1297 (2018) Bonomo R.A. Burd E.M. Conly J. Limbago B.M. Poirel L. Segre J.A. Westblade L.F. : Carbapenemase-Producing Organisms: A Global Scourge . Clin. Infect. Dis . 66 , 1290 – 1297 ( 2018 ) Search in Google Scholar

11. Botelho J., Grosso F., Sousa C., Peixe L.: Characterization of a new genetic environment associated with GES-6 carbapenemase from a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235. J. Antimicrob. Chemother. 70, 615–617 (2015) Botelho J. Grosso F. Sousa C. Peixe L. : Characterization of a new genetic environment associated with GES-6 carbapen-emase from a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 . J. Antimicrob. Chemother . 70 , 615 – 617 ( 2015 ) Search in Google Scholar

12. Bouchet F., Atze H., Fonvielle M., Edoo Z., Arthur M., Ethève-Quelquejeu M., Iannazzo L.: Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria. J Med Chem. 63, 5257–5273 (2020) Bouchet F. Atze H. Fonvielle M. Edoo Z. Arthur M. Ethève-Quelquejeu M. Iannazzo L. : Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria . J Med Chem . 63 , 5257 – 5273 ( 2020 ) Search in Google Scholar

13. Bush K., Jacoby G.A.: Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54, 969–976 (2010) Bush K. Jacoby G.A. : Updated functional classification of β-lactamases . Antimicrob. Agents Chemother . 54 , 969 – 976 ( 2010 ) Search in Google Scholar

14. Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q1 2024. Available at: https://www.gov.uk/government/publications/carbapenemase-producing-gram-negative-bacteria-laboratory-surveillance/carbapenemase-producing-gram-negative-organisms-in-england-since-october-2020-quarterly-update-q1-2024 (accessed on 25.07.2024) Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q1 2024 . Available at: https://www.gov.uk/government/publications/carbapenemase-producing-gram-negative-bacteria-laboratory-surveillance/carbapenemase-producing-gram-negative-organisms-in-england-since-october-2020-quarterly-update-q1-2024 (accessed on 25.07.2024 ) Search in Google Scholar

15. Chmielewska S., Leszczyńska K.: Carbapenemase of intestinal rods – the beginning of post-antibiotic era? Advancements of Microbiology, 58, 271–289 (2019) Chmielewska S. Leszczyńska K. : Carbapenemase of intestinal rods – the beginning of post-antibiotic era? Advancements of Microbiology , 58 , 271 – 289 ( 2019 ) Search in Google Scholar

16. Egorov A., Rubtsova M., Grigorenko V., Uporov I., Veselovsky A.: The Role of the Ω-Loop in Regulation of the Catalytic Activity of TEM-Type β-Lactamases. Biomolecules, 9, 854 (2019) Egorov A. Rubtsova M. Grigorenko V. Uporov I. Veselovsky A. : The Role of the Ω-Loop in Regulation of the Catalytic Activity of TEM-Type β-Lactamases . Biomolecules , 9 , 854 ( 2019 ) Search in Google Scholar

17. Electronic Medicines Compendium. 2024. “Nitrofurantoin 100 mg Capsules. Summary of Product Characteristics.” Available at: https://www.medicines.org.uk/emc/product/428/smpc#gref(accessed on 10.07.2024) Electronic Medicines Compendium . 2024 . “ Nitrofurantoin 100 mg Capsules . Summary of Product Characteristics .” Available at: https://www.medicines.org.uk/emc/product/428/smpc#gref (accessed on 10.07.2024 ) Search in Google Scholar

18. Ellington M.J. & Holmes A. et al.: A Multispecies Cluster of GES-5 Carbapenemase-Producing Enterobacterales Linked by a Geographically Disseminated Plasmid. Clin. Infect. Dis. 71, 2553-2560 (2020) Ellington M.J. Holmes A. et al. : A Multispecies Cluster of GES-5 Carbapenemase-Producing Enterobacterales Linked by a Geographically Disseminated Plasmid . Clin. Infect. Dis . 71 , 2553 ( 2020 ) Search in Google Scholar

19. Escandón K., Reyes S., Gutiérrez S., Villegas M.: The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Review of Anti-infective Therapy. 15, 277–297 2017) Escandón K. Reyes S. Gutiérrez S. Villegas M. : The epidemiology of carbapenemases in Latin America and the Caribbean . Expert Review of Anti-infective Therapy . 15 , 277 – 297 ( 2017 ) Search in Google Scholar

20. European Medicine Agency. 2018. “Vabomere (meropenem/vaborbactam). An overview of Vabomere and why it is authorized in the E.U.” Available at: https://www.ema.europa.eu/en/documents/overview/vabomere-epar-medicine-overview_en.pdf(accessed on 10.07.2024) European Medicine Agency . 2018 . “ Vabomere (meropenem/vaborbactam). An overview of Vabomere and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/docu-ments/overview/vabomere-epar-medicine-overview_en.pdf (accessed on 10.07.2024 ) Search in Google Scholar

21. European Medicine Agency. 2022. “Recarbrio (imipenem/cilastatin/relebactam). An overview of Recarbrio and why it is authorized in the E.U.” Available at: https://www.ema.europa. eu/en/documents/overview/recarbrio-epar-medicine-overview_ en.pdf (accessed on 10.07.2024) European Medicine Agency . 2022 . “ Recarbrio (imipenem/cilastatin/relebactam). An overview of Recarbrio and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/documents/overview/recarbrio-epar-medicine-overview_en.pdf (accessed on 10.07.2024 ) Search in Google Scholar

22. European Medicine Agency. 2024b. “Xerava (eravacycline). An overview of Xerava and why it is authorized in the E.U.” Available at: https://www.ema.europa.eu/en/documents/overview/xerava-epar-medicine-overview_en.pdf (accessed on 10.07.2024) European Medicine Agency . 2024b . “ Xerava (eravacycline). An overview of Xerava and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/documents/overview/xerava-epar-medicine-overview_en.pdf (accessed on 10.07.2024 ) Search in Google Scholar

23. European Medicine Agency. 2024c. “Zavicefta (ceftazidime/avibactam). An overview of Zavicefta and why it is authorized in the E.U.” Available at: https://www.ema.europa.eu/en/documents/overview/zavicefta-epar-medicine-overview_en.pdf (accessed on 10.07.2024) European Medicine Agency . 2024c . “ Zavicefta (ceftazidime/avibactam). An overview of Zavicefta and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/documents/overview/zavicefta-epar-medicine-overview_en.pdf (accessed on 10.07.2024 ) Search in Google Scholar

24. European Medicines Agency. 2020a. “ Fetcroja (cefiderocol). An overview of Fetcroja and why it is authorized in the E.U.” Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja (accessed on 10.07.2024) European Medicines Agency . 2020a . “ Fetcroja (cefiderocol). An overview of Fetcroja and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja (accessed on 10.07.2024 ) Search in Google Scholar

25. European Medicines Agency. 2020b. “Xenleta (lefamulin). An overview of Xenleta and why it is authorized in the E.U.” Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/xenleta (accessed on 10.07.2024) European Medicines Agency . 2020b . “ Xenleta (lefamulin). An overview of Xenleta and why it is authorized in the E.U .” Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/xenleta (accessed on 10.07.2024 ) Search in Google Scholar

26. European Medicines Agency. 2024a. “Exblifep (cefepime/enmetazobactam). An overview of Exblifep and why it is authorised in the E.U.” Available at: https://www.ema.europa.eu/en/documents/overview/exblifep-epar-medicine-overview_en.pdf (accessed on 10.07.2024) European Medicines Agency . 2024a . “ Exblifep (cefepime/enmetazobactam). An overview of Exblifep and why it is authorised in the E.U .” Available at: https://www.ema.europa.eu/en/documents/overview/exblifep-epar-medicine-overview_en.pdf (accessed on 10.07.2024 ) Search in Google Scholar

27. Frase H., Smith C.A., Toth M., Champion M.M., Mobashery S., Vakulenko S.B.: Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry. J. Biol. Chem. 286, 14396–409 (2011) Frase H. Smith C.A. Toth M. Champion M.M. Mobashery S. Vakulenko S.B. : Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry . J. Biol. Chem . 286 , 14396 – 409 ( 2011 ) Search in Google Scholar

28. Garza-Ramos U., Barrios H., Reyna-Flores F., Tamayo-Legorreta E., Catalan-Najera J.C., Morfin-Otero R., Rodríguez-Noriega E., Volkow P., Cornejo-Juarez P., González A., Gaytan-Martinez J., Del Rocío Gónzalez-Martínez M., Vazquez-Farias M., Silva-Sanchez J.: Widespread of ESBL- and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals. Diagn Microbiol Infect Dis. 81(2), 135–137 (2015) Garza-Ramos U. Barrios H. Reyna-Flores F. Tamayo-Legorreta E. Catalan-Najera J.C. Morfin-Otero R. Rodríguez-Noriega E. Volkow P. Cornejo-Juarez P. González A. Gaytan-Martinez J. Del Rocío Gónzalez-Martínez M. Vazquez-Farias M. Silva-Sanchez J. : Widespread of ESBL-and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals . Diagn Microbiol Infect Dis . 81 ( 2 ), 135 – 137 ( 2015 ) Search in Google Scholar

29. Grossman T.H., O’Brien W., Kerstein K.O., Sutcliffe J.A.: Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother. 59, 2446–2449 (2015) Grossman T.H. O’Brien W. Kerstein K.O. Sutcliffe J.A. : Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli . Antimicrob Agents Chemother . 59 , 2446 – 2449 ( 2015 ) Search in Google Scholar

30. Hawkey P.M., Warren R.E., Livermore D.M., McNulty C.A.M., Enoch D.A., Otter J.A., Wilson A.P.R.: Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J. Antimicrob. Chemother. 73, iii2–iii78 (2018) Hawkey P.M. Warren R.E. Livermore D.M. McNulty C.A.M. Enoch D.A. Otter J.A. Wilson A.P.R. : Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party . J. Antimicrob. Chemother . 73 , iii2 – iii78 ( 2018 ) Search in Google Scholar

31. Hayden D.A., White B.P., Bennett K.K.: Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales. J Pharm Technol. 36, 202–210 (2020) Hayden D.A. White B.P. Bennett K.K. : Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales . J Pharm Technol . 36 , 202 – 210 ( 2020 ) Search in Google Scholar

32. Herrera-Espejo S., Del Barrio-Tofiño E., Cebrero-Cangueiro T., López-Causapé C., Álvarez-Marín R., Cisneros J.M., Pachón J., Oliver A., Pachón-Ibáñez M.E.: Carbapenem Combinations for Infections Caused by Carbapenemase-Producing Pseudomonas aeruginosa: Experimental In Vitro and In Vivo Analysis. Antibiotics (Basel), 11, 1212 (2022) Herrera-Espejo S. Del Barrio-Tofiño E. Cebrero-Cangueiro T. López-Causapé C. Álvarez-Marín R. Cisneros J.M. Pachón J. Oliver A. Pachón-Ibáñez M.E. : Carbapenem Combinations for Infections Caused by Carbapenemase-Producing Pseudomonas aeruginosa: Experimental In Vitro and In Vivo Analysis . Antibiotics (Basel) , 11 , 1212 ( 2022 ) Search in Google Scholar

33. Hryniewicz W.: 2023. “Leki przeciwbakteryjne”. Avaliable at: https://www.mp.pl/interna/chapter/B16.II.18.11.1. (accessed on 10.07.2024) Hryniewicz W. : 2023. “Leki przeciwbakteryjne ”. Avaliable at: https://www.mp.pl/interna/chapter/B16.II.18.11.1 . (accessed on 10.07.2024 ) Search in Google Scholar

34. Juan C. Vázquez-Ucha, Jorge Arca-Suárez, Germán Bou, Alejandro Beceiro: New Carbapenemase Inhibitors: Clearing the Way for the β-lactams. Int J Mol Sci. 21, 9308 (2020) Juan C. Vázquez-Ucha Jorge Arca-Suárez Germán Bou Alejandro Beceiro : New Carbapenemase Inhibitors: Clearing the Way for the β-lactams . Int J Mol Sci . 21 , 9308 ( 2020 ) Search in Google Scholar

35. Kotsakis S.D., Miriagou V., Tzelepi E., Tzouvelekis L.S.: Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrob. Agents Chemother. 54, 4864–71 (2010) Kotsakis S.D. Miriagou V. Tzelepi E. Tzouvelekis L.S. : Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases . Antimicrob. Agents Chemother . 54 , 4864 – 71 ( 2010 ) Search in Google Scholar

36. Labuschagne Cde J., Weldhagen G.F., Ehlers M.M., Dove M.G.: Emergence of class 1 integron-associated GES-5 and GES-5-like extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa. Int J Antimicrob Agents. 31(6), 527–530 (2008) Labuschagne Cde J. Weldhagen G.F. Ehlers M.M. Dove M.G. : Emergence of class 1 integron-associated GES-5 and GES-5-like extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa . Int J Antimicrob Agents . 31 ( 6 ), 527 – 530 ( 2008 ) Search in Google Scholar

37. Levitt P.S., Papp-Wallace K.M., Taracila M.A., Hujer A.M., Winkler M.L., Smith K.M., Xu Y., Harris M.E., Bonomo R.A.: Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J. Biol. Chem. 287, 31783–31793 (2012) Levitt P.S. Papp-Wallace K.M. Taracila M.A. Hujer A.M. Winkler M.L. Smith K.M. Xu Y. Harris M.E. Bonomo R.A. : Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis . J. Biol. Chem . 287 , 31783 – 31793 ( 2012 ) Search in Google Scholar

38. Mabrouk A., Grosso F., Botelho J., Achour W., Ben Hassen A., Peixe L.: GES-14-Producing Acinetobacter baumannii Isolates in a Neonatal Intensive Care Unit in Tunisia Are Associated with a Typical Middle East Clone and a Transferable Plasmid. Antimicrob Agents Chemother. 61(6), e00142–17 (2017) Mabrouk A. Grosso F. Botelho J. Achour W. Ben Hassen A. Peixe L. : GES-14-Producing Acinetobacter baumannii Isolates in a Neonatal Intensive Care Unit in Tunisia Are Associated with a Typical Middle East Clone and a Transferable Plasmid . Antimicrob Agents Chemother . 61 ( 6 ), e00142 – 17 ( 2017 ) Search in Google Scholar

39. Mammeri H., Van De Loo M., Poirel L., Martinez-Martinez L., Nordmann P.: Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother. 49, 71–76 (2005) Mammeri H. Van De Loo M. Poirel L. Martinez-Martinez L. Nordmann P. : Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe . Antimicrob. Agents Chemother . 49 , 71 – 76 ( 2005 ) Search in Google Scholar

40. Mendez-Sotelo B.J., López-Jácome L.E., Colín-Castro C.A., Hernández-Durán M., Martínez-Zavaleta M.G., Rivera-Buendía F., Velázquez-Acosta C., Rodríguez-Zulueta A.P., Morfín-Otero M.D.R., Franco-Cendejas R.: Comparison of Lateral Flow Immunochromatography and Phenotypic Assays to PCR for the Detection of Carbapenemase-Producing Gram-Negative Bacteria, a Multicenter Experience in Mexico. Antibiotics (Basel). 12(1), 96 (2023) Mendez-Sotelo B.J. López-Jácome L.E. Colín-Castro C.A. Hernández-Durán M. Martínez-Zavaleta M.G. Rivera-Buendía F. Velázquez-Acosta C. Rodríguez-Zulueta A.P. Morfín-Otero M.D.R. Franco-Cendejas R. : Comparison of Lateral Flow Immunochromatography and Phenotypic Assays to PCR for the Detection of Carbapenemase-Producing Gram-Negative Bacteria, a Multicenter Experience in Mexico . Antibiotics (Basel) . 12 ( 1 ), 96 ( 2023 ) Search in Google Scholar

41. Moubareck C., Brémont S., Conroy M.C., Courvalin P., Lambert T.: GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob. Agents Chemother. 53, 3579–3581 (2009) Moubareck C. Brémont S. Conroy M.C. Courvalin P. Lambert T. : GES-11, a novel integron-associated GES variant in Acinetobacter baumannii . Antimicrob. Agents Chemother . 53 , 3579 ( 2009 ) Search in Google Scholar

42. Muntean M.M., Muntean A.A., Gauthier L., Creton E., Cotellon G., Popa M.I., Bonnin R.A., Naas T.: Evaluation of the rapid carbapenem inactivation method (rCIM): a phenotypic screening test for carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 73(4), 900–908 (2018) Muntean M.M. Muntean A.A. Gauthier L. Creton E. Cotellon G. Popa M.I. Bonnin R.A. Naas T. : Evaluation of the rapid carbap-enem inactivation method (rCIM): a phenotypic screening test for carbapenemase-producing Enterobacteriaceae . J Antimicrob Chemother . 73 ( 4 ), 900 – 908 ( 2018 ) Search in Google Scholar

43. Ortiz-Cartagena C., Pablo-Marcos D., Fernández-García L., Blasco L., Pacios O., Bleriot I. et al.: CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases. Microbiol Spectr. 11, e01329–23 (2023) Ortiz-Cartagena C. Pablo-Marcos D. Fernández-García L. Blasco L. Pacios O. Bleriot I. et al. : CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapen-emases . Microbiol Spectr . 11 , e01329 – 23 ( 2023 ) Search in Google Scholar

44. Pablo-Marcos D., Siller M., Agüero J., Álvarez-Justel A., García-Fernández S., Velasco de la Fuente S., Goicoechea P., Rodríguez-Lozano J., Ocampo-Sosa A., Lucas-Fernández J., Fariñas M.C., Fernández J., Fraile-Ribot P.A., Aracil B., Oteo-Iglesias J., Calvo-Montes J.: Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation, J. Microbiol. Methods, 207, (2023) Pablo-Marcos D. Siller M. Agüero J. Álvarez-Justel A. García-Fernández S. Velasco de la Fuente S. Goicoechea P. Rodríguez-Lozano J. Ocampo-Sosa A. Lucas-Fernández J. Fariñas M.C. Fernández J. Fraile-Ribot P.A. Aracil B. Oteo-Iglesias J. Calvo-Montes J. : Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation , J. Microbiol. Methods , 207 , ( 2023 ) Search in Google Scholar

45. Pasteran F., Gonzalez L.J., Albornoz E., Bahr G., Vila A.J., Corso A.: Triton Hodge Test: Improved Protocol for Modified Hodge Test for Enhanced Detection of NDM and Other Car-bapenemase Producers. J Clin Microbiol. 54(3), 640–649 (2016) Pasteran F. Gonzalez L.J. Albornoz E. Bahr G. Vila A.J. Corso A. : Triton Hodge Test: Improved Protocol for Modified Hodge Test for Enhanced Detection of NDM and Other Car-bapenemase Producers . J Clin Microbiol . 54 ( 3 ), 640 – 649 ( 2016 ) Search in Google Scholar

46. Paterson D.L., Bonomo R.A.: Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657–686 (2005) Paterson D.L. Bonomo R.A. : Extended-spectrum beta-lactamases: a clinical update . Clin. Microbiol. Rev . 18 , 657 – 686 ( 2005 ) Search in Google Scholar

47. Wernicki P.: Trojański antybiotyk; działa skutecznie, bo podstępnie; rynekaptek.pl; 2018. Available online: https://www. rynekaptek.pl/farmakologia/trojanski-antybiotyk-dziala-skutecznie-bo-podstepnie,28760.html (accessed on 10.07.2024) Wernicki P. : Trojański antybiotyk; działa skutecznie, bo podstęp-nie; rynekaptek.pl; 2018 . Available online: https://www.rynekaptek.pl/farmakologia/trojanski-antybiotyk-dziala-skutecznie-bo-podstepnie,28760.html (accessed on 10.07.2024 ) Search in Google Scholar

48. Poirel L., Le Thomas I., Naas T., Karim A., Nordmann P.: Biochemical Sequence Analyses of GES-1, a Novel Class A Extended-Spectrum β-Lactamase, and the Class 1 Integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother, 44, (2000) Poirel L. Le Thomas I. Naas T. Karim A. Nordmann P. : Biochemical Sequence Analyses of GES-1, a Novel Class A Extended-Spectrum β-Lactamase, and the Class 1 Integron In52 from Klebsiella pneumoniae . Antimicrob Agents Chemother , 44 , ( 2000 ) Search in Google Scholar

49. Poirel L., Nordmann P.: Rapid tests for detection of carbapenemase producers in P. aeruginosa; what do we really need? Enferm. Infecc. Microbiol. Clin. 32, 623–624 (2014) Poirel L. Nordmann P. : Rapid tests for detection of carbap-enemase producers in P. aeruginosa; what do we really need? Enferm. Infecc. Microbiol. Clin . 32 , 623 – 624 ( 2014 ) Search in Google Scholar

50. Poirel L., Ortiz De La Rosa J.M., Kieffer N., Dubois V., Jayol A., Nordmann P.: Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa. Antimicrob. Agents Chem-other. 63, e01809–18 (2018) Poirel L. Ortiz De La Rosa J.M. Kieffer N. Dubois V. Jayol A. Nordmann P. : Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa . Antimicrob. Agents Chem-other . 63 , e01809 – 18 ( 2018 ) Search in Google Scholar

51. Poirel L., Weldhagen G.F., Naas T., De Champs C., Dove M.G., Nordmann P.: GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother, 45, 2598–2603 (2001) Poirel L. Weldhagen G.F. Naas T. De Champs C. Dove M.G. Nordmann P. : GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem . Antimicrob Agents Chemother , 45 , 2598 – 2603 ( 2001 ) Search in Google Scholar

52. Queenan A.M., Bush K.: Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 20, 440–458 (2007) Queenan A.M. Bush K. : Carbapenemases: the versatile betalactamases . Clin. Microbiol. Rev . 20 , 440 ( 2007 ) Search in Google Scholar

53. Ramana K.V., Rao R., Sharada Ch.V., Kareem M., Reddy L.R., Ratna Mani M.: Modified Hodge test: A useful and the low-cost phenotypic method for detection of carbapenemase producers in Enterobacteriaceae members. J Nat Sci Biol Med. 4(2), 346–8 (2013) Ramana K.V. Rao R. Sharada Ch.V. Kareem M. Reddy L.R. Ratna Mani M. : Modified Hodge test: A useful and the low-cost phenotypic method for detection of carbapenemase producers in Enterobacteriaceae members . J Nat Sci Biol Med . 4 ( 2 ), 346 – 8 ( 2013 ) Search in Google Scholar

54. Recio R., Villa J., González-Bodí S., Brañas P., Orellana M.Á., Mancheño-Losa M., Lora-Tamayo J., Chaves F., Viedma E.: Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 Pseudomonas aeruginosa Isolates. Antibiotics (Basel). 11, 871 (2022) Recio R. Villa J. González-Bodí S. Brañas P. Orellana M.Á. Mancheño-Losa M. Lora-Tamayo J. Chaves F. Viedma E. : Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 Pseudomonas aeruginosa Isolates . Antibiotics (Basel) . 11 , 871 ( 2022 ) Search in Google Scholar

55. Rejestr produktów leczniczych. 2012. “Charakterystyka produktu leczniczego Monural.” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/4453/characteristic(accessed on 10.07.2024) Rejestr produktów leczniczych . 2012 . “ Charakterystyka produktu leczniczego Monural .” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/4453/characteristic (accessed on 10.07.2024 ) Search in Google Scholar

56. Rejestr produktów leczniczych. 2014. “Charakterystyka produktu leczniczego Colistin TZF.” Available at: https://rejestry.ezdrowie. gov.pl/api/rpl/medicinal-products/1541/characteristic(accessed on 10.07.2024) Rejestr produktów leczniczych . 2014 . “ Charakterystyka produktu leczniczego Colistin TZF .” Available at: https://rejestry.ezdrowie.gov.pl/api/rpl/medicinal-products/1541/characteristic (accessed on 10.07.2024 ) Search in Google Scholar

57. Rejestr produktów leczniczych. 2015a. “Charakterystyka produktu leczniczego Tobramycin B. Braun.” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/23763/characteristic(accessed on 10.07.2024) Rejestr produktów leczniczych . 2015a . “ Charakterystyka produktu leczniczego Tobramycin B. Braun .” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/23763/characteristic (accessed on 10.07.2024 ) Search in Google Scholar

58. Rejestr produktów leczniczych. 2015b. “Charakterystyka produktu leczniczego Amikacin B. Braun.” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/25694/characteristic(accessed on 10.07.2024) Rejestr produktów leczniczych . 2015b . “ Charakterystyka produktu leczniczego Amikacin B. Braun .” Available at: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/25694/characteristic (accessed on 10.07.2024 ) Search in Google Scholar

59. Rezzoug I., Emeraud C., Sauvadet A., Cotellon G., Naas T., Dortet L.: Evaluation of a colorimetric test for the rapid detection of carbapenemase activity in Gram negative bacilli: the MAST® PAcE test. Antimicrob Agents Chemother. 95(5), e02351-20 (2023) Rezzoug I. Emeraud C. Sauvadet A. Cotellon G. Naas T. Dortet L. : Evaluation of a colorimetric test for the rapid detection of carbapenemase activity in Gram negative bacilli: the MAST® PAcE test . Antimicrob Agents Chemother . 95 ( 5 ), e02351 – 20 ( 2023 ) Search in Google Scholar

60. Smith C.A., Frase H., Toth M., Kumarasiri M., Wiafe K., Munoz J., Mobashery S., Vakulenko S.B.: Structural basis for progression toward the carbapenemase activity in the GES family of betalactamases. J AM CHEM SOC. 134(47), 19512–19515 (2012) Smith C.A. Frase H. Toth M. Kumarasiri M. Wiafe K. Munoz J. Mobashery S. Vakulenko S.B. : Structural basis for progression toward the carbapenemase activity in the GES family of betalactamases . J AM CHEM SOC . 134 ( 47 ), 19512 – 19515 ( 2012 ) Search in Google Scholar

61. Smith C.A., Caccamo M., Kantardjieff K.A., Vakulenko S.: Structure of GES-1 at atomic resolution: insights into the evolution of carbapenamase activity in the class A extended-spectrum betalactamases. Acta Crystallogr D Biol Crystallogr. 9, 982–92 (2007) Smith C.A. Caccamo M. Kantardjieff K.A. Vakulenko S. : Structure of GES-1 at atomic resolution: insights into the evolution of carbapenamase activity in the class A extended-spectrum betalactamases . Acta Crystallogr D Biol Crystallogr . 9 , 982 – 92 ( 2007 ) Search in Google Scholar

62. Soszyńska-Morys D, Wawer A.: Nowe antybiotyki w badaniach klinicznych – perspektywy rozwoju leczenia przeciwbakteryjnego. Med Og Nauk Zdr. 29, 73–78 (2023) Soszyńska-Morys D Wawer A. : Nowe antybiotyki w badaniach klinicznych – perspektywy rozwoju leczenia przeciwbakteryj-nego . Med Og Nauk Zdr . 29 , 73 – 78 ( 2023 ) Search in Google Scholar

63. Streling A.P., Barbosa P.P., Marcondes M.F., Nicoletti A.G., Picão R.C., Pinto E.C., Marques E.A., Oliveira V., Gales A.C.: Genetic and biochemical characterization of GES-16, a new GES-type β-lactamase with carbapenemase activity in Serratia marcescens. Diagn. Microbiol. Infect. Dis. 92, 147–151 (2018) Streling A.P. Barbosa P.P. Marcondes M.F. Nicoletti A.G. Picão R.C. Pinto E.C. Marques E.A. Oliveira V. Gales A.C. : Genetic and biochemical characterization of GES-16, a new GES-type β-lactamase with carbapenemase activity in Serratia marcescens . Diagn. Microbiol. Infect. Dis . 92 , 147 – 151 ( 2018 ) Search in Google Scholar

64. Tanabe M., Sugawara Y., Denda T., Sakaguchi K., Takizawa S.: Municipal wastewater monitoring revealed the predominance of blaGES genes with diverse variants among carbapenemase-producing organisms: high occurrence and persistence of Aero-monas caviae harboring the new blaGES variant blaGES-48. Microbiol Spectr. 6 (2023) Tanabe M. Sugawara Y. Denda T. Sakaguchi K. Takizawa S. : Municipal wastewater monitoring revealed the predominance of blaGES genes with diverse variants among carbapenemase-producing organisms: high occurrence and persistence of Aero-monas caviae harboring the new blaGES variant blaGES-48 . Microbiol Spectr . 6 ( 2023 ) Search in Google Scholar

65. Tenover FC.: Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections. Front Cell Infect Microbiol. 11, 1–6 (2021) Tenover FC. : Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections . Front Cell Infect Microbiol . 11 , 1 – 6 ( 2021 ) Search in Google Scholar

66. Vanstone GL, Wey E, Mack D, Smith ER, Balakrishnan I.: Evaluation of the EntericBio CPE assay for the detection of carba-penemase-producing organisms. J Med Microbiol. 67, 1728–1730 (2018) Vanstone GL Wey E Mack D Smith ER Balakrishnan I. : Evaluation of the EntericBio CPE assay for the detection of carba-penemase-producing organisms . J Med Microbiol . 67 , 1728 – 1730 ( 2018 ) Search in Google Scholar

67. Viedma E., Juan C., Acosta J., Zamorano L., Otero J.R., Sanz F., Chaves F., Oliver A.: Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother. 53(11), 4930–3 (2009) Viedma E. Juan C. Acosta J. Zamorano L. Otero J.R. Sanz F. Chaves F. Oliver A. : Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain . Antimicrob Agents Chemother . 53 ( 11 ), 4930 – 3 ( 2009 ) Search in Google Scholar

68. Vourli S., Giakkoupi P., Miriagou V., Tzelepi E., Vatopoulos A.C., Tzouvelekis L.S.: Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria, FEMS Microbiol. Lett. 234, 209–213 (2006) Vourli S. Giakkoupi P. Miriagou V. Tzelepi E. Vatopoulos A.C. Tzouvelekis L.S. : Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria, FEMS Microbiol. Lett . 234 , 209 – 213 ( 2006 ) Search in Google Scholar

69. Wachino J., Doi Y., Yamane K., Shibata N., Yagi T., Kubota T., Arakawa Y. Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A β-Lactamase, GES-4, Possessing a Single G170S Substitution in the Ω-Loop. Antimicrob Agents Chemother, 48, (2004) Wachino J. Doi Y. Yamane K. Shibata N. Yagi T. Kubota T. Arakawa Y. , Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A β-Lactamase, GES-4, Possessing a Single G170S Substitution in the Ω-Loop . Antimicrob Agents Chemother , 48 , ( 2004 ) Search in Google Scholar

70. World Health Organization. 2024. "WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.” WHO. Available online: https://www.who.int/publications/i/item/9789240093461(accessed on 10.07.2024) World Health Organization . 2024 . " WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance .” WHO . Available online: https://www.who.int/publications/i/item/9789240093461 (accessed on 10.07.2024 ) Search in Google Scholar

71. Zhanel G.G., Cheung D., Adam H., Zelenitsky S., Golden A., Schweizer F., Gorityala B., Lagacé-Wiens P.R., Walkty A., Gin A.S., Hoba D.J., Karlowsky J.A.: Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs, 76(5), 567–88 (2016) Zhanel G.G. Cheung D. Adam H. Zelenitsky S. Golden A. Schweizer F. Gorityala B. Lagacé-Wiens P.R. Walkty A. Gin A.S. Hoba D.J. Karlowsky J.A. : Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent . Drugs , 76 ( 5 ), 567 – 88 ( 2016 ) Search in Google Scholar